CA-INTEGRA
21.6.2022 15:47:07 CEST | Business Wire | Press release
Integra, a leading provider of innovative RF and Microwave Power solutions that help make a safer and more connected world, today announced it has begun production shipments to US and European customers of its groundbreaking 100V RF GaN technology. Tom Kole, Integra’s Vice President of Sales and Marketing, said, “In collaboration with our customers, our system engineers have helped design new radar architectures that take full advantage of the benefits of our third generation 100V RF GaN technology. It’s exciting to see Integra’s 100V RF GaN products move into production with customers as it signifies another industry first.”
Integra also announced expansion of their 100V RF GaN product portfolio with the introduction of 7 new products for avionics, directed energy, electronic warfare, radar and scientific market segments with power levels up to 5kW in a single transistor. These products incorporate Integra’s 100V RF GaN technology optimized to deliver the highest power and efficiency in a single transistor while maintaining reliable operating junction temperatures. Combined with Integra’s thermally enhanced patents and transistor design expertise, these products offer reliable operation with a MTTF of 107 hours. Suja Ramnath, Integra’s President and CEO, said, “Integra has spent a decade innovating, maturing and commercializing our groundbreaking 100V RF GaN technology. Building upon our 25 year heritage of semiconductor innovation, this 3rd generation 100V RF GaN continues to extend our technical and market leadership.”
Additionally, Integra’s partner Teledyne e2v HiRel is offering high reliability options for all of Integra's 100V RF GaN power devices and pallets targeted at the defense market. Brad Little, Vice President and General Manager of Teledyne e2v HiRel, said, “Our space customers can benefit from Integra’s 100V RF GaN products combined with Teledyne’s expertise and long heritage providing space RF components. These innovative products offer space payload engineers state-of-the-art power devices for insertion into their applications.”
New 100V RF GaN parts introduced:
Part Number |
Description |
Market |
IGW4000 |
100V, Ultra-Wideband Multi Chip Module |
Electronic Warfare |
IGN1012S2500 |
100V, 2.5kW L Band Directed Energy Transistor |
Directed Energy |
IGN1030S3100 |
75V, 3.1kW L Band Avionics Transistor |
Avionics |
IGN1030S3600 |
100V, 3.6kW L-Band Avionics Transistor |
Avionics |
IGN1313S3600 |
100V, 3.6kW 1.3GHz Scientific Transistor |
Scientific |
IGN1214M3200 |
75V, 3.2kW 1.2-1.4GHz, L Band Radar Transistor |
L-Band Radar |
IGN2729M1500 |
100V, 1.5kW 2.7-2.9GHz, S Band Radar Transistor |
S-Band Radar |
ABOUT INTEGRA TECHNOLOGIES, INC.
Founded in 1997, Integra is a leading innovator of RF and Microwave high power semiconductor and pallet solutions for mission-critical applications, including state-of-the-art radar, electronic warfare and advanced communications systems. www.integratech.com .
ABOUT TELEDYNE E2V HIREL ELECTRONICS
Teledyne e2v HiRel innovations lead developments in space, transportation, defense and industrial markets. Teledyne e2v’s unique approach involves listening to the market and to the application challenges of customers and partnering with our customers to provide innovative standard, semi-custom or fully custom solutions, bringing increased value to their systems. Teledyne e2v HiRel Electronics is part of the Teledyne Defense Electronics Group. www.tdehirel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
